Results With Cyclosporine Monotherapy in Long-Term Cardiac Transplant Recipients

Abstract Background Triple therapy is the gold standard after heart transplantation while few reports have described experiences with cyclosporine monotherapy (CM). We have analyzed our experience with CM in long-term heart transplant recipients, surviving >5 years. Methods Of the 219 patients tr...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2010-05, Vol.42 (4), p.1291-1293
Main Authors: Sansone, F, Boffini, M, Comoglio, C, Checco, L, Saviolo, R, Centofanti, P, La Torre, M, Rinaldi, M
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Adult
Azathioprine - therapeutic use
Biological and medical sciences
Cyclosporine - therapeutic use
Drug Therapy, Combination
Female
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Heart Transplantation - immunology
Heart Transplantation - mortality
Humans
Immunosuppressive Agents - therapeutic use
Male
Medical sciences
Middle Aged
Patient Selection
Postoperative Complications - epidemiology
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Survival Rate
Survivors
Time Factors
Tissue Donors - statistics & numerical data
Tissue, organ and graft immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Triple therapy is the gold standard after heart transplantation while few reports have described experiences with cyclosporine monotherapy (CM). We have analyzed our experience with CM in long-term heart transplant recipients, surviving >5 years. Methods Of the 219 patients transplanted between January 1990 and December 1998, 143 survived >5 years (mean age, 49.6 ± 10.4). There were 124 (86.7%) male subjects. Matching patients respect to follow-up length, we obtained 2 groups: group A of 41 patients on double therapy (DT; cyclosporine plus Azathioprine) and group B of 41 patients on CM. Results After a mean follow-up of 119.8 ± 32.2 months, we did not observe a significant difference in terms of survival and major events: heart failure, malignancy, dialysis, infections, and CAV. Conclusion We strongly support the use of triple therapy in cardiac transplant recipients because of its known safety and efficacy. However, our experience with CM suggests the utility of this approach.
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2010.03.126